Are drug-eluting stents cost-effective? It depends on whom you ask

Circulation

Volumn 114, Issue 16, 2006, Pages 1736-1743

  Ryan, Jason ^a   Cohen, David J ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; FUNDING; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEART MUSCLE REVASCULARIZATION; HOSPITAL; HOSPITAL COST; HUMAN; IMPLANT; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MEDICARE; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY RESTENOSIS; CORONARY STENOSIS; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; HUMANS; STENTS;

EID: 33750215672     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.546010     Document Type: Note

References (40)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein P, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, for the RAVEL Study Group. Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
5. Tanne JH. Use of drug eluting stents increases in the US but only for some groups. BMJ. 2004;329:1205.
6. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
7. Kong DF, Eisenstein EL, Sketch MH Jr, Zidar JP, Ryan TJ, Harrington RA, Newman MF, Smith PK, Mark DB, Califf RM. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J. 2004;147:449-456.
8. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol. 2004;43:513-518.
9. Anderson GF, Hussey PS, Frogner BK, Waters HR. Health spending in the United States and the rest of the industrialized world. Health Aff (Millwood). 2005;24:903-914.
10. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Yokoi H, Hamasaki N, Nosaka H, Nobuyoshi M. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561-566.
11. Bennett MR, O'Sullivan M. Mechanism of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther. 2001;91:149-166.
12. Weintraub WS, Ghazzal ZM, Douglas JS Jr, Liberman HA, Morris DC, Cohen CL, King SB. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 1993;87:831-840.
13. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA, for the Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
14. Rihal CS, Raco DL, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. Circulation. 2003;108:2439-2445.
15. Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T, D'Haem C, Clark VL, Martin JS, Cohen DJ, Neil N, Every NR. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet. 2000;355:2199-2203.
16. Rinfret S, Grines CL, Cosgrove RS, Ho KK, Cox DA, Brodie BR, Morice MC, Stone GW, Cohen DJ, for the Stent-PAMI Investigators. Quality of life after balloon angioplasty or stenting for acute myocardial infarction: one-year results from the Stent-PAMI trial. J Am Coll Cardiol. 2001;38:1614-1621.
17. Cohen DJ, Cosgrove R, Berezin R, O'Shea C, Tcheng J, for the ESPRIT Investigators. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: results from the ESPRIT trial. Circulation. 2001;104(suppl I):I-386-I-387. Abstract.
18. Cohen DJ, Cosgrove RS, Berezin R, Teirstein P, Leon M, Kuntz R. Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation. 2002;106:691-697.
19. Reynolds MR, Neil N, Ho KK, Berezin R, Cosgrove R, Lager R, Sirois C, Johnson RG, Cohen DJ. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center U.S. experience. Am Heart J. 2003;145:334-342.
20. Clark MA, Bakhai A, Lacey MJ, Pelletier EM, Cohen DJ. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of Medicare claims data. Circulation. 2004;110:259-264.
21. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, Cohen DJ, Kuntz RE. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-2089.
22. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE, for the SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
23. Cohen DJ, O'Shea JC, Pacchiana CM, Levine G, Sarembock I, Slater J, Conn E, Smith J, Tcheng JE, for the ESPRIT Investigators. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial): Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrillin. Am J Cardiol. 2002;89:61-64.
24. Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS, Weinstein MC. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: use of a decision-analytic model. Circulation. 1994;89:1859-1874.
25. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005;294:819-825.
26. Weinstein M, Stason W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
27. Greenberg D, Cohen DJ. Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. Z Kardiol. 2002;91(suppl 3):137-143.
28. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet. 1998;352:673-681.
29. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) trial. Circulation. 2001;104:3039-3045.
30. van Hout BA, Serruys PW, Lemos PA, van den Brand MJ, van Es GA, Lindeboom WK, Morice MC. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart. 2005;91:507-512.
31. Greenberg D, Bakhai A, Neumann PJ, Cohen DJ. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy. 2004;70:207-216.
32. Baim DS, Cutlip DE, Midei M, Linnemeier TJ, Schreiber T, Cox D, Kereiakes D, Popma JJ, Robertson L, Prince R, Lansky AJ, Ho KK, Kuntz RE, for the ASCENT Investigators (ACS Multi-Link Stent Clinical Equivalence in De Novo Lesions Trial). Final results of a randomized trial comparing the MUTLI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001;87:157-62.
33. Bakhai A, Stone G, Mahoney E, Lavelle T, Shi C, Berezin R, Lahue B, Clark M, Lacey M, Russell M, Ellis S, Hermiller J, Cox D, Cohen DJ, for the TAXUS-IV Investigators. Cost-effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006;48:253-261.
34. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME, for the BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet. 2005;366:921-929.
35. Greenberg D, Bakhai A, Neil N, Berezin R, Ho K, Cutlip D, Kuntz R, Cohen DJ. Modeling the impact of patient and lesion characteristics on the cost-effectiveness of drug-eluting stents. J Am Coll Cardiol. 2003;41(suppl):538A. Abstract.
36. Centers for Medicare and Medicaid Services Website. Available at: http://www.cms.hhs.gov/. Accessed June 7, 2006.
37. Dulisse B, Zhang J, Ryan J, Macaya C, Columbo A, Garcia H, Wittebols K, Van Hout B, Cohen DJ. Cost-effectiveness of PCI with or without drug-eluting stents vs. bypass surgery for treatment of multivessel coronary disease: 1-year results from the ARTS I and ARTS II trials. Abstract presented at: 2005 American Heart Association Scientific Sessions; November 15, 2005; Dallas, Tex.
38. Liddicoat J, De La Torre R, Ho K, Nathan S, Levitsky S, Krempin J, Sellke F. Initial impact of drug-eluting stents on coronary artery bypass graft surgery. Ann Thorac Surg. 2006;81:1239-1242.
39. Vaina S, Stefanadis C. Detection of the vulnerable coronary atheromatous plaque: where are we now? Int J Cardiovasc Intervent. 2005;7:75-87.
40. Virmani R, Burke A. Farb A, Kolodgie F. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13-C18.